The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
Nathan M Radcliffe Ophthalmology, New York University, New York, NY, USA Abstract: Glaucomatous optic atrophy is the second most common cause of blindness worldwide, and lowering intraocular pressure (IOP) is the only proven method to slow or stop the progression of the disease. Approximately 40%...
Enregistré dans:
Auteur principal: | Radcliffe NM |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/5aef8b2261c0435b9664d2c60ef48a3e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
par: Nicholas P Bell, et autres
Publié: (2010) -
Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate
par: Jaime Pablo Kelly Rigollet, et autres
Publié: (2011) -
Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
par: Yoshikawa K, et autres
Publié: (2014) -
Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
par: Jordão MLS, et autres
Publié: (2014) -
Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy
par: Norbert Pfeiffer, et autres
Publié: (2010)